244 related articles for article (PubMed ID: 29512864)
1. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
2. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
3. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kitoh T; Kawaguchi H; Goto H; Kosaka Y; Tsunematsu Y; Imashuku S;
Int J Hematol; 2018 Aug; 108(2):192-198. PubMed ID: 29594922
[TBL] [Abstract][Full Text] [Related]
4. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
Gadner H; Heitger A; Grois N; Gatterer-Menz I; Ladisch S
Med Pediatr Oncol; 1994; 23(2):72-80. PubMed ID: 8202045
[TBL] [Abstract][Full Text] [Related]
5. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
6. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
7. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
8. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
[TBL] [Abstract][Full Text] [Related]
9. The 5-Year EFS of Multisystem LCH With Risk-Organ Involvement Is Suboptimal: A Single-center Experience From India.
Totadri S; Bansal D; Trehan A; Srinivasan R; Varma N; Kakkar N; Saxena AK; Bhatia P
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e1-5. PubMed ID: 26274033
[TBL] [Abstract][Full Text] [Related]
10. Outcome of High-risk Langerhans Cell Histiocytosis (LCH) in Egyptian Children, Does Intermediate-dose Methotrexate Improve the Outcome?
Sedky MS; Hamouda A; Taha H; Zaky I; Hassanain O; El Hemaly A; ElHaddad A
J Pediatr Hematol Oncol; 2019 Nov; 41(8):635-643. PubMed ID: 30247183
[TBL] [Abstract][Full Text] [Related]
11. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
[TBL] [Abstract][Full Text] [Related]
13. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
14. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H;
Med Pediatr Oncol; 2002 Dec; 39(6):581-5. PubMed ID: 12376981
[TBL] [Abstract][Full Text] [Related]
15. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group.
Morimoto A; Shimazaki C; Takahashi S; Yoshikawa K; Nishimura R; Wakita H; Kobayashi Y; Kanegane H; Tojo A; Imamura T; Imashuku S;
Int J Hematol; 2013 Jan; 97(1):103-8. PubMed ID: 23243004
[TBL] [Abstract][Full Text] [Related]
17. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
[TBL] [Abstract][Full Text] [Related]
18. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
19. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience.
Derenzini E; Stefoni V; Pellegrini C; Gandolfi L; Broccoli A; Casadei B; Quirini F; Argnani L; Tonialini L; Zinzani PL
BMC Cancer; 2015 Nov; 15():879. PubMed ID: 26552668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
